Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638840 | 1.00 | KDM4E (0.43) | KDM4EMAPTSSTR4USP30NR1H2 | |
| SCHEMBL20586011 | 0.81 | RAB9A (0.38) | KDM4EHTT | |
| SCHEMBL20586012 | 0.81 | RAB9A (0.38) | KDM4EHTT | |
| SCHEMBL20586014 | 0.81 | RAB9A (0.38) | KDM4EHTT | |
| SCHEMBL20587746 | 0.81 | RAB9A (0.38) | KDM4EHTT | |
| SCHEMBL2279416 | 0.80 | KDM4E (0.48) | KDM4EMAPTUSP30EEDRBBP4 | |
| SCHEMBL22326469 | 0.80 | SSTR4 (0.43) | SSTR4USP30NR1H2JAK3EED | |
| SCHEMBL16210462 | 0.78 | SSTR4 (0.39) | SSTR4USP30NR1H2JAK3GPR119 | |
| SCHEMBL16210459 | 0.78 | SSTR4 (0.39) | SSTR4USP30NR1H2JAK3GPR119 | |
| SCHEMBL16210458 | 0.78 | SSTR4 (0.39) | SSTR4USP30NR1H2JAK3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352342-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10752610-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-10329278-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | KDM4E 3256/4885MAPT 1525/4885SSTR4 391/4885 |
| US-11352342-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | KDM4E 3256/4885MAPT 1525/4885SSTR4 391/4885 |
| US-10329278-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | KDM4E 3255/4885MAPT 1420/4885SSTR4 355/4885 |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | KDM4E 3256/4885MAPT 1525/4885SSTR4 391/4885 |
| US-10752610-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | KDM4E 3256/4885MAPT 1525/4885SSTR4 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.